Risk factors for tumor enlargement suggested by previous studies include documented tumor growth before starting pegvisomant, withdrawal of somatostatin analog therapy that previously produced tumor shrinkage (21C23) and no previous radiotherapy (23C28)
Risk factors for tumor enlargement suggested by previous studies include documented tumor growth before starting pegvisomant, withdrawal of somatostatin analog therapy that […]